Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients

R. Iliev, M. Stanik, M. Fedorko, A. Poprach, P. Vychytilova-Faltejskova, K. Slaba, M. Svoboda, P. Fabian, D. Pacik, J. Dolezel, O. Slaby,

. 2016 ; 9 (-) : 217-22. [pub] 20160108

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010878

Grantová podpora
NV15-34678A MZ0 CEP - Centrální evidence projektů

Piwi-interacting RNAs (piRNAs) are a newly discovered class of small non-coding RNAs involved in silencing of transposable elements and in sequence-specific chromatin modifications. PIWI proteins (PIWIL), which belong to the family of Argonaute genes/proteins, bind to piRNAs and function mainly in germ line cells, but more recently were described to be functional also in stem cells and cancer cells. To date, there have been four PIWI proteins discovered in humans: PIWIL1, PIWIL2, PIWIL3, and PIWIL4. Recent studies suggested that deregulated expression of PIWI proteins and selected piRNAs is common to many types of cancers. We found significantly lower expression of PIWIL1 (P<0.0001) and piR-823 (P=0.0001) in tumor tissue in comparison to paired renal parenchyma. Further, we observed a progressive decrease in PIWIL1 (P=0.0228), PIWIL2 (P=0.0015), and PIWIL4 (P=0.0028) expression levels together with increasing clinical stage. PIWIL2 (P=0.0073) and PIWIL4 (P=0.0001) expression also progressively decreased with increasing Fuhrman grade. Most importantly, low-expression levels of PIWIL1 (P=0.009), PIWIL2 (P<0.0001), and PIWIL4 (P=0.0065) were significantly associated with worse overall survival in renal cell carcinoma (RCC) patients. Our results suggest the involvement of PIWIL genes and piR-823 in RCC pathogenesis, and indicate PIWIL1, PIWIL2, and PIWIL4 as potential prognostic biomarkers in patients with RCC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010878
003      
CZ-PrNML
005      
20201116155009.0
007      
ta
008      
160408s2016 nz f 000 0|engg|
009      
AR
024    7_
$a 10.2147/OTT.S91295 $2 doi
024    7_
$a 10.2147/OTT.S91295 $2 doi
035    __
$a (PubMed)26811690
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Iliev, Robert $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
245    10
$a Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients / $c R. Iliev, M. Stanik, M. Fedorko, A. Poprach, P. Vychytilova-Faltejskova, K. Slaba, M. Svoboda, P. Fabian, D. Pacik, J. Dolezel, O. Slaby,
520    9_
$a Piwi-interacting RNAs (piRNAs) are a newly discovered class of small non-coding RNAs involved in silencing of transposable elements and in sequence-specific chromatin modifications. PIWI proteins (PIWIL), which belong to the family of Argonaute genes/proteins, bind to piRNAs and function mainly in germ line cells, but more recently were described to be functional also in stem cells and cancer cells. To date, there have been four PIWI proteins discovered in humans: PIWIL1, PIWIL2, PIWIL3, and PIWIL4. Recent studies suggested that deregulated expression of PIWI proteins and selected piRNAs is common to many types of cancers. We found significantly lower expression of PIWIL1 (P<0.0001) and piR-823 (P=0.0001) in tumor tissue in comparison to paired renal parenchyma. Further, we observed a progressive decrease in PIWIL1 (P=0.0228), PIWIL2 (P=0.0015), and PIWIL4 (P=0.0028) expression levels together with increasing clinical stage. PIWIL2 (P=0.0073) and PIWIL4 (P=0.0001) expression also progressively decreased with increasing Fuhrman grade. Most importantly, low-expression levels of PIWIL1 (P=0.009), PIWIL2 (P<0.0001), and PIWIL4 (P=0.0065) were significantly associated with worse overall survival in renal cell carcinoma (RCC) patients. Our results suggest the involvement of PIWIL genes and piR-823 in RCC pathogenesis, and indicate PIWIL1, PIWIL2, and PIWIL4 as potential prognostic biomarkers in patients with RCC.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stanik, Michal $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Fedorko, Michal $u Department of Urology, University Hospital Brno, Masaryk University Brno, Brno, Czech Republic.
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Vychytilova-Faltejskova, Petra $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Slaba, Katerina $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Fabian, Pavel $u Department of Diagnostic and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Pacik, Dalibor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Dolezel, Jan $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Urology, University Hospital Brno, Masaryk University Brno, Brno, Czech Republic.
773    0_
$w MED00165461 $t OncoTargets and therapy $x 1178-6930 $g Roč. 9, č. - (2016), s. 217-22
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26811690 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20201116155007 $b ABA008
999    __
$a ind $b bmc $g 1114307 $s 935246
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 9 $c - $d 217-22 $e 20160108 $i 1178-6930 $m OncoTargets and therapy $n OncoTargets ther. $x MED00165461
GRA    __
$a NV15-34678A $p MZ0
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace